Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2013 | short review | Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013

ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2013
Autor:
Prof. Dr. Andreas L. Petzer

Abstract

At the recent ASH meeting, updated 4 year results on the use of the second-generation tyrosine kinase inhibitor nilotinib compared with imatinib were presented and they demonstrated superiority in achieving faster and deeper molecular responses for nilotinib compared to imatinib. A rapid decrease in BCR-ABL transcripts of ≤ 10 % BCR-ABL IS at 3 months is associated with a statistically significantly superior overall survival regardless which tyrosine kinase inhibitor was used (nilotinib, dasatinib, and imatinib). By using a second-generation tyrosine kinase inhibitor, however, the chance to achieve ≤ 10 % BCR-ABL IS at 3 months is significantly higher. Some data also indicate that some caution should be taken for new and so far unknown potential side effects of second-generation tyrosine kinase inhibitors.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe